Today's trade is in a mental health biotech company focused on developing psychedelic-assisted therapies — primarily a synthetic form of psilocybin called COMP360 — for difficult-to-treat psychiatric conditions.
After being hit hard in 2025, the group has spent most of the year repairing damage and trying to find its footing while much of the market has gone vertical.
If there is anything more volatile than my PnL, it is often my mental state. It's not something I'm proud of. When I'm winning, I'm often ebullient. When I'm losing, I'm usually pretty sullen. This sucks for me and...